Alnylam Pharmaceuticals

ALNY

Market cap $59.6B

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stock is trading higher on Friday, with no news to justify the movement.

The Virtus Silvant Mid-Cap Growth Fund returned +5.43% (Class INST) for the quarter, compared to the Russell Midcap Growth Index's return of +2.78%. Palantir Technologies (PLTR) and Roblox (RBLX) were among the top stock contributors. Fair Isaac Corp. (FICO) and Verisk Analytics (VRSK) were among the largest stock detractors.

The S&P 500's TJX is among the five stocks to watch showing resilience in a tough market

The UK's drug cost-effectiveness watchdog has recommended Alnylam Pharmaceuticals' heart disease drug, ensuring access for patients through the government health system in England and Wales, the company said on Friday.

Alnylam stock is holding its 50-day moving average as it seeks to get back to its buy point of 484.21.

Alnylam Pharmaceuticals, Inc. ( ALNY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP & Chief Commercial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maurice Raycroft, and I'm one of the Biotech Analysts at Jefferies.

Here is how Alnylam Pharmaceuticals (ALNY) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Alnylam Pharmaceuticals boasts an exciting product lineup and pipeline. IonQ could be one of the biggest winners in the fast-growing quantum computing market.

Alnylam Pharmaceuticals, Inc. ( ALNY ) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Jeffrey Poulton - CFO & Executive VP John Vest - Senior Vice President of Clinical Research Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Data from cardiovascular magnetic re.